• One Health
  • Pain Management
  • Oncology
  • Anesthesia
  • Geriatric & Palliative Medicine
  • Ophthalmology
  • Anatomic Pathology
  • Poultry Medicine
  • Infectious Diseases
  • Dermatology
  • Theriogenology
  • Nutrition
  • Animal Welfare
  • Radiology
  • Internal Medicine
  • Small Ruminant
  • Cardiology
  • Dentistry
  • Feline Medicine
  • Soft Tissue Surgery
  • Urology/Nephrology
  • Avian & Exotic
  • Preventive Medicine
  • Anesthesiology & Pain Management
  • Integrative & Holistic Medicine
  • Food Animals
  • Behavior
  • Zoo Medicine
  • Toxicology
  • Orthopedics
  • Emergency & Critical Care
  • Equine Medicine
  • Pharmacology
  • Pediatrics
  • Respiratory Medicine
  • Shelter Medicine
  • Parasitology
  • Clinical Pathology
  • Virtual Care
  • Rehabilitation
  • Epidemiology
  • Fish Medicine
  • Diabetes
  • Livestock
  • Endocrinology

Successful tolerability study of CBD products for dogs

Article

The National Animal Supplement Council has shared positive results from a recent CBD study

EKKAPON / stock.adobe.com

EKKAPON / stock.adobe.com

The National Animal Supplement Council (NASC) conducted a study on female and male dogs in which they tested the tolerability of broad spectrum cannabidiol (CBD), broad spectrum CBD with cannabigerol (CBG) and broad-spectrum CBD with cannabidiolic acid (CBDA). According to a release from the NASC,1 the study was randomized, non-blinded, negative controlled, and a parallel design repeat dose. Sixteen male dogs and 16 female dogs at least 6-months of age were randomly placed into 4 groups and given either medium chain triglyceride oil as the control or one of the following: a broad spectrum cannabidiol, a broad spectrum cannabidiol with cannabigerol, or a broad spectrum cannabidiol with cannabidiolic acid at 5 mg total cannabinoids/kg body weight/day for 90 consecutive days. Animals were observed daily with detailed clinical examinations conducted weekly.

Upon completion, all animals were reported to have no serious adverse events reported during the study. Based on the data collected, it was concluded by the authors that these substances do not pose significant risk to dogs in long-term use.1

“Part of what makes this study unique is the data from support from the NASC’s Adverse Event Reporting System (NAERS) which is the most advanced system of post market surveillance in the world,” said Bill Bookout, president of NASC, in the release. “Through this system, NASC members enter their products, ingredients, administration recommendations into the NAERS database along with the number of units in each container provided to customers. These collective data are processed by algorithms in the system and Adverse Events, both serious and non-serious can be compared and analyzed per million administrations.”

Nutrasource director of preclinical and companion animal services, Margitta Dziwenka, DVM, DABT stated in the release, "This research is a game-changer for pet health offering an expanded horizon for veterinarians, industry, and pet owners alike. These findings grant us a renewed sense of confidence in exploring CBD product development for use in companion animals, so that industry can confidently answer the call and growing demand for natural and alternative products.”1

Reference

NASC announces successful tolerability study of cannabidiol products in healthy dogs. News release. National Animal Supplement Council. Published May 16, 2023. Accessed May 31, 2023.

Related Videos
Cat and lilies
© 2024 MJH Life Sciences

All rights reserved.